All filters
Slidesets
In vivo evaluation of anti-HBV CRISPR/Cas9 therapy in the FRG mouse- Dr. K. Jerome
Presented at:
HEP DART 2017
Slidesets
Development of Immune Competent Small Animal Models for HBV- Helene Strick-Marchand
Presented at:
HEP DART 2017
Slidesets
Emerging Therapeutic Targets and Concepts for Delta Hepatitis Virus (not yet available) - Jeffrey Glenn
Presented at:
HEP DART 2017
Slidesets
Revisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination- Fabien Zoulim, MD, PhD
Presented at:
HEP DART 2017
Slidesets
HEV Update: Diagnostics and Management- Kenneth Sherman, MD, PhD
Presented at:
HEP DART 2017
Slidesets
Is There a Best Host Acting Antiviral for HBV Cure?- Jake Liang
Presented at:
HEP DART 2017
Slidesets
Is there a best immunomodulator in development?- Ulrike Protzer
Presented at:
HEP DART 2017
Slidesets
Is there a best Direct Acting Antiviral in development?- Fabien Zoulim, MD, PhD
Presented at:
HEP DART 2017
Slidesets
New directions towards functional cure of Chronic Hepatitis B- Lawrence Blatt, PhD
Presented at:
HEP DART 2017
Slidesets
Looking back to move forward: designing next-gen RNAi for best results in HBV- Bruce Given
Presented at:
HEP DART 2017
Slidesets
SB 9200: A novel RIG-I agonist for chronic hepatitis B- Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Presented at:
HEP DART 2017
Slidesets
Studies of the HBV-immune modulator AIC649 (not yet available)- Helga Rübsamen-schaeff
Presented at:
HEP DART 2017
Slidesets
Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure- Michael Sofia, PhD
Presented at:
HEP DART 2017
Slidesets
Eliminating HCV Transmission by Enhancing Care and Treatment Among HCV/HIV Co-infected Individuals in Australia (not available)- Joseph Doyle, MD
Presented at:
HEP DART 2017
Slidesets
Management of HCV in Decompensated liver disease- Michael Manns
Presented at:
HEP DART 2017
Slidesets
DAA Controversies: Do they Cause HBV Reactivation and/or HCC?- Jordan Feld, MD, MPH
Presented at:
HEP DART 2017
Slidesets
Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination- Tarik Asselah
Presented at:
HEP DART 2017
Slidesets
When are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR? (not available)- Paul Pockros
Presented at:
HEP DART 2017